GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Telesis Bio Inc (NAS:TBIO) » Definitions » Piotroski F-Score

Telesis Bio (Telesis Bio) Piotroski F-Score : 3 (As of May. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Telesis Bio Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Telesis Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Telesis Bio's Piotroski F-Score or its related term are showing as below:

TBIO' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 3   Max: 4
Current: 3

During the past 5 years, the highest Piotroski F-Score of Telesis Bio was 4. The lowest was 3. And the median was 3.


Telesis Bio Piotroski F-Score Historical Data

The historical data trend for Telesis Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telesis Bio Piotroski F-Score Chart

Telesis Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 4.00 3.00 3.00

Telesis Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 3.00 3.00 3.00

Competitive Comparison of Telesis Bio's Piotroski F-Score

For the Medical Devices subindustry, Telesis Bio's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telesis Bio's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Telesis Bio's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Telesis Bio's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -11.119 + -8.287 + -10.631 + -17.687 = $-47.72 Mil.
Cash Flow from Operations was -11.167 + -10.3 + -5.888 + -7.312 = $-34.67 Mil.
Revenue was 6.316 + 8.652 + 5.564 + 6.977 = $27.51 Mil.
Gross Profit was 3.511 + 5.693 + 2.997 + 4.749 = $16.95 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(81.362 + 89.162 + 114.526 + 105.029 + 70.411) / 5 = $92.098 Mil.
Total Assets at the begining of this year (Dec22) was $81.36 Mil.
Long-Term Debt & Capital Lease Obligation was $32.56 Mil.
Total Current Assets was $30.35 Mil.
Total Current Liabilities was $8.18 Mil.
Net Income was -13.194 + -14.831 + -12.314 + -8.132 = $-48.47 Mil.

Revenue was 5.636 + 5.655 + 6.675 + 9.469 = $27.44 Mil.
Gross Profit was 2.778 + 2.712 + 3.659 + 6.446 = $15.60 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(116.257 + 111.134 + 97.284 + 88.142 + 81.362) / 5 = $98.8358 Mil.
Total Assets at the begining of last year (Dec21) was $116.26 Mil.
Long-Term Debt & Capital Lease Obligation was $20.79 Mil.
Total Current Assets was $55.09 Mil.
Total Current Liabilities was $13.50 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Telesis Bio's current Net Income (TTM) was -47.72. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Telesis Bio's current Cash Flow from Operations (TTM) was -34.67. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-47.724/81.362
=-0.58656375

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-48.471/116.257
=-0.41692973

Telesis Bio's return on assets of this year was -0.58656375. Telesis Bio's return on assets of last year was -0.41692973. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Telesis Bio's current Net Income (TTM) was -47.72. Telesis Bio's current Cash Flow from Operations (TTM) was -34.67. ==> -34.67 > -47.72 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=32.558/92.098
=0.35351473

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=20.79/98.8358
=0.21034888

Telesis Bio's gearing of this year was 0.35351473. Telesis Bio's gearing of last year was 0.21034888. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=30.351/8.184
=3.70857771

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=55.092/13.498
=4.08149355

Telesis Bio's current ratio of this year was 3.70857771. Telesis Bio's current ratio of last year was 4.08149355. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Telesis Bio's number of shares in issue this year was 30.012. Telesis Bio's number of shares in issue last year was 29.565. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=16.95/27.509
=0.61616198

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=15.595/27.435
=0.56843448

Telesis Bio's gross margin of this year was 0.61616198. Telesis Bio's gross margin of last year was 0.56843448. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=27.509/81.362
=0.33810624

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=27.435/116.257
=0.23598579

Telesis Bio's asset turnover of this year was 0.33810624. Telesis Bio's asset turnover of last year was 0.23598579. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Telesis Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Telesis Bio  (NAS:TBIO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Telesis Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Telesis Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Telesis Bio (Telesis Bio) Business Description

Traded in Other Exchanges
N/A
Address
10431 Wateridge Circle, Suite 150, San Diego, CA, USA, 92121
Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services. Its products comprise of BioXp system, BioXp kits, Benchtop reagents, Coronavirus tools, and BioXp biofoundry services.
Executives
Gregory J. Herrema director 355 RIVER OAKS PARKWAY, SAN JOSE CA 95134
Marijn E Dekkers 10 percent owner GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Novalis Lifesciences Investments Ii Gp, Llc 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Novalis Lifesciences Investments Ii, L.p. 10 percent owner 1 LIBERTY LANE E, SUITE 112, HAMPTON NH 03842
Broadoak Fund Iv, Llc 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
William Snider director, 10 percent owner 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Paul M Meister director, 10 percent owner 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
Rob Cutler officer: Chief Legal Officer C/O TELESIS BIO, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Daniel Glenn Gibson officer: Chief Technology Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Todd Robert Nelson director, 10 percent owner, officer: President & CEO C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Eric Eugene Esser officer: Chief Operating Officer C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO CA 92121
Annette Tumolo director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Northpond Ventures Gp, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814
Northpond Ventures Gp Ii, Llc 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BESTHESDA MD 20814
Northpond Ventures Ii, Lp 10 percent owner 7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814